Overview

Open Label Extension Study of AMX0035 in Patients With ALS

Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the Centaur study.
Phase:
Phase 2
Details
Lead Sponsor:
Amylyx Pharmaceuticals Inc.
Collaborator:
Massachusetts General Hospital Neurology Clinical Research Institute